LUCENT Appoints Simon Doyle as CEO

LUCENT Biopharma Ltd. has appointed Simon Doyle as CEO with immediate effect. 

As LUCENT enters its next phase of growth, this leadership change will ensure the continued strength of its culture and reputation, with Doyle providing the leadership required to deliver the three-year growth strategy, while Goodman remains focused on the delivery of Medical Affairs expertise to LUCENTs clients.

Doyle said: "Having worked closely with LUCENT, I've seen first-hand the strength of its model and the calibre of its people. As CEO my focus will be on scaling the business in a way that preserves its entrepreneurial spirit and commitment to excellence."

This leadership expansion marks a significant step in LUCENT's ambition to build a world-class Medical Affairs consultancy. Central to LUCENT's approach is its commitment to a medical-led team, ensuring every function is aligned to client needs and real-world challenges.